Business
AstraZeneca likely to run new COVID-19 vaccine trial, CEO says, as questions emerge – Sydney Morning Herald
The company is likely to conduct an additional global vaccine trial after current studies raised questions over its level of protection.
Soriot said he didn’t expect the additional trial to hold up regulatory approvals in the UK and European Union.
Clearance from the US Food and Drug Administration may take longer because the regulator is unlikely to approve the vaccine on the basis of studies conducted elsewhere, especially given the questions over the results, he said. Authorisation in some countries is still expected before the end of the year, he said.
AstraZeneca and its CEO are facing scrutiny as the drugmaker responds to growing…
-
Noosa News9 hours agoHow Lily Steele-Park took her rapist to court and won
-
General23 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business14 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Business12 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025